Copper in Alzheimer's disease

too much or too little?

Joseph Quinn, Susanne Crane, Christopher Harris, Teri L. Wadsworth

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therAβy and copper supplementation therAβy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalExpert Review of Neurotherapeutics
Volume9
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Copper
Alzheimer Disease
Clinical Trials

Keywords

  • Alzheimer's disease
  • Animal model
  • Chelation
  • Clinical trial
  • Copper
  • Oxidative damage

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Copper in Alzheimer's disease : too much or too little? / Quinn, Joseph; Crane, Susanne; Harris, Christopher; Wadsworth, Teri L.

In: Expert Review of Neurotherapeutics, Vol. 9, No. 5, 05.2009, p. 631-637.

Research output: Contribution to journalArticle

Quinn, Joseph ; Crane, Susanne ; Harris, Christopher ; Wadsworth, Teri L. / Copper in Alzheimer's disease : too much or too little?. In: Expert Review of Neurotherapeutics. 2009 ; Vol. 9, No. 5. pp. 631-637.
@article{e72de5d6fae34841a28d6eff4878c2bd,
title = "Copper in Alzheimer's disease: too much or too little?",
abstract = "A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therAβy and copper supplementation therAβy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.",
keywords = "Alzheimer's disease, Animal model, Chelation, Clinical trial, Copper, Oxidative damage",
author = "Joseph Quinn and Susanne Crane and Christopher Harris and Wadsworth, {Teri L.}",
year = "2009",
month = "5",
doi = "10.1586/ern.09.27",
language = "English (US)",
volume = "9",
pages = "631--637",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Copper in Alzheimer's disease

T2 - too much or too little?

AU - Quinn, Joseph

AU - Crane, Susanne

AU - Harris, Christopher

AU - Wadsworth, Teri L.

PY - 2009/5

Y1 - 2009/5

N2 - A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therAβy and copper supplementation therAβy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.

AB - A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therAβy and copper supplementation therAβy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.

KW - Alzheimer's disease

KW - Animal model

KW - Chelation

KW - Clinical trial

KW - Copper

KW - Oxidative damage

UR - http://www.scopus.com/inward/record.url?scp=66249101638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249101638&partnerID=8YFLogxK

U2 - 10.1586/ern.09.27

DO - 10.1586/ern.09.27

M3 - Article

VL - 9

SP - 631

EP - 637

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 5

ER -